HomeCompareAKBTY vs ABBV

AKBTY vs ABBV: Dividend Comparison 2026

AKBTY yields 2.57% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $78.8K in total portfolio value
10 years
AKBTY
AKBTY
● Live price
2.57%
Share price
$3.03
Annual div
$0.08
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.5K
Annual income
$303.12
Full AKBTY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — AKBTY vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAKBTYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AKBTY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AKBTY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AKBTY
Annual income on $10K today (after 15% tax)
$218.30/yr
After 10yr DRIP, annual income (after tax)
$257.65/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,798.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AKBTY + ABBV for your $10,000?

AKBTY: 50%ABBV: 50%
100% ABBV50/50100% AKBTY
Portfolio after 10yr
$62.9K
Annual income
$12,537.44/yr
Blended yield
19.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AKBTY
No analyst data
Altman Z
-0.2
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AKBTY buys
0
ABBV buys
0
No recent congressional trades found for AKBTY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAKBTYABBV
Forward yield2.57%3.06%
Annual dividend / share$0.08$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$23.5K$102.3K
Annual income after 10y$303.12$24,771.77
Total dividends collected$2.8K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AKBTY vs ABBV ($10,000, DRIP)

YearAKBTY PortfolioAKBTY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,957$256.83$11,550$430.00$593.00ABBV
2$11,987$262.99$13,472$627.96$1.5KABBV
3$13,095$268.89$15,906$926.08$2.8KABBV
4$14,286$274.53$19,071$1,382.55$4.8KABBV
5$15,566$279.90$23,302$2,095.81$7.7KABBV
6$16,940$285.03$29,150$3,237.93$12.2KABBV
7$18,416$289.91$37,536$5,121.41$19.1KABBV
8$20,000$294.54$50,079$8,338.38$30.1KABBV
9$21,699$298.95$69,753$14,065.80$48.1KABBV
10$23,521$303.12$102,337$24,771.77$78.8KABBV

AKBTY vs ABBV: Complete Analysis 2026

AKBTYStock

Akbank T.A.S., together with its subsidiaries, provides various banking products and services in Turkey and internationally. It operates through: Retail Banking; Commercial Banking, SME Banking, Corporate-Investment and Private Banking; and Treasury segments. The company's retail banking services comprise deposit accounts, retail loans, commercial installment loans, credit cards, insurance products, and asset management services, as well as bank cards, investment funds trading, automatic payment, foreign currency trading, safe deposit box rental, cheques, money transfer, investment banking, and telephone and internet banking. It also offers services to large, medium, and small size corporate and commercial customers that include Turkish Lira (TL) and foreign currency denominated working capital loans financing for investments, foreign trade financing, derivative instruments for hedging purposes of foreign currency and interest risk, letters of credit, foreign currency trading, corporate finance, and deposit and cash management services, as well as project finance loans; and timely and permanent solutions for corporate customers' working capital management, delivering cash management services based on customers' requests that include collection and payment services and liquidity and information management. In addition, the company engages in treasury activities consisting of TL and foreign currency spot and forward transactions, treasury and government bonds, Eurobonds, and private sector bond transactions, as well as derivative trading activities; and marketing and pricing activities related treasury products. Further, it provides financial leasing services, stock exchange brokerage services, and portfolio management, as well as offers payment services and issues electronic money. As of December 31, 2021, the company operated 710 branches. Akbank T.A.S. was founded in 1948 and is headquartered in Istanbul, Turkey.

Full AKBTY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AKBTY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AKBTY vs SCHDAKBTY vs JEPIAKBTY vs OAKBTY vs KOAKBTY vs MAINAKBTY vs JNJAKBTY vs MRKAKBTY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.